Citation: Bw. Bode et P. Strange, Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes, DIABET CARE, 24(1), 2001, pp. 69-72
Authors:
Mudaliar, SRD
Mohideen, P
Baxi, SC
Joyce, M
Armstrong, DA
Strange, P
Henry, RR
Citation: Srd. Mudaliar et al., Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation, CLIN THER, 23(3), 2001, pp. 404-412
Authors:
Vincent, C
Taylor-Adams, S
Chapman, EJ
Hewett, D
Prior, S
Strange, P
Tizzard, A
Citation: C. Vincent et al., How to investigate and analyse clinical incidents: Clinical risk unit and association of litigation and risk management protocol, BR MED J, 320(7237), 2000, pp. 777-781
Authors:
Mudaliar, SR
Lindberg, FA
Joyce, M
Beerdsen, P
Strange, P
Lin, A
Henry, RR
Citation: Sr. Mudaliar et al., Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin - absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects, DIABET CARE, 22(9), 1999, pp. 1501-1506